Personal Information

Personal Statement

• ​Associate Professor, Zhongshan School of Medicine, Sun Yat-sen University, 2021 - Present
• ​Distinguished Research Fellow, Sun Yat-sen University, 2019 - 2021
• ​Distinguished Associate Research Fellow, Sun Yat-sen University, 2016 - 2019
• ​Doctoral Candidate, Pharmacology, Sun Yat-sen University, 2011 - 2016

Research Interests

My research focuses on oncolytic viruses, specifically on the molecular mechanisms underlying their tumor-targeting properties, immunological characteristics, and the development of novel viral strains. As the first author or corresponding author, I have published 10 research articles in prestigious international journals such as Nature Communications, PNAS, Oncogene, and Molecular Oncology. These studies elucidated the molecular mechanism by which the oncolytic virus M1 naturally targets tumor cells. Based on the interaction between the M1 virus and tumor cells, we have identified a series of synergistic targets.

As the principal investigator, I have successfully secured funding for 6 projects from national, provincial, municipal, and institutional sources, including 3 National Natural Science Foundation of China grants, as well as projects from the Natural Science Foundation of Guangdong Province and Guangzhou Municipal Science and Technology Projects for People's Livelihood. In 2021, I was awarded the Outstanding Young Scientist Project of the Natural Science Foundation of Guangdong Province.

Academic Achievements

Journal Articles

• Liang J, Guo L, Li K, Xiao X, Zhu W, Zheng X, Hu J, Zhang H, Cai J, Yu Y, Tan Y, Li C, Liu X, Hu C, Liu Y, Qiu P, Su X, He S, Lin Y, Yan G (2018) Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus. Nature communications 9(1):1524
• Xiao X, Liang J (co-first author), Huang C, Li K, Xing F, Zhu W, Lin Z, Xu W, Wu G, Zhang J, Lin X, Tan Y, Cai J, Hu J, Chen X, Huang Y, Qin Z, Qiu P, Su X, Chen L, Lin Y, Zhang H, Yan G (2018) DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nature communications 9(1):4342
• Cai J, Liu W, Wong CW, Zhu W, Lin Y, Hu J, Xu W, Zhang J, Sander M, Wang Z, Dan J, Zhang J, Liu Y, Guo L, Qin Z, Liu X, Liu Y, Yan G, Wu S, Liang J (corresponding author) (2020) Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene 39(37):5995 - 6008
• Cai J, Lin K, Cai W, Lin Y, Liu X, Guo L, Zhang J, Xu W, Lin Z, Wong CW, Sander M, Hu J, Yan G, Zhu W, Liang J (corresponding author) (2020) Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1. Molecular oncology 14(12):3153 - 3168
• Liu Y, Cai J, Liu W, Lin Y, Guo L, Liu X, Qin Z, Xu C, Zhang Y, Su X, Deng K, Yan G, Liang J (corresponding author) (2020) Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. Cell death & disease 11(12):1062
• Cai J, Zhu W, Lin Y, Zhang S, Chen X, Gong S, He S, Hu J, Yan G, Liang J (corresponding author) (2020) Systematic Characterization of the Biodistribution of the Oncolytic Virus M1. Human gene therapy 31(21 - 22):1203 - 1213
• Lin Y, Zhang HP, Liang JK(co-first author), Li K, Zhu WB, Fu LW, Wang F, Zheng XK, Shi HJ, Wu SH, Xiao X, Chen LJ, Tang LP, Yan M, Yang XX, Tan YQ, Qiu PX, Huang YJ, Yin W, Su XW, Hu HY, Hu J, Yan GM (2014) Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. PNAS 111(42):E4504 - E4512
• Dan J, Nie L, Jia X, Xu C, Cai J, Lin Y, Hu J, Zhu W, Li Y, Chen D, Liu Y, Hu C, Yan G, Liang J (co-corresponding author), Zhang Q (2021) Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells. Virologica Sinica
• Liu Y, Li K, Zhu WB, Zhang H, Huang WT, Liu XC, Lin Y, Cai J, Yan GM, Qiu JG, Peng L, Liang JK (co-corresponding author), Hu C (2021) Suppression of CCDC6 sensitizes tumor to oncolytic virus M1. Neoplasia 23(1):158 - 168
• Cai J, Zhu W, Lin Y, Hu J, Liu X, Xu W, Liu Y, Hu C, He S, Gong S, Yan G, Liang J (corresponding author) (2020) Lonidamine potentiates the oncolytic efficiency of M1 virus independent of hexokinase 2 but via inhibition of antiviral immunity. Cancer cell international 20(1):532